Malta - English - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - omeprazole - gastro-resistant capsule - omeprazole 10 mg - drugs for acid related disorders

Malta - English - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - omeprazole - gastro-resistant capsule - omeprazole 20 mg - drugs for acid related disorders

Malta - English - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - omeprazole - gastro-resistant capsule - omeprazole 40 mg - drugs for acid related disorders

Malta - English - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin - tablet - vildagliptin 50 mg - drugs used in diabetes

Malta - English - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - English - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - vildagliptin, metformin hydrochloride - film-coated tablet - vildagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Malta - English - Medicines Authority

holsten pharma gmbh hahnstraße 31-35 60528 frankfurt am main , germany - prucalopride succinate - film-coated tablet - prucalopride succinate 1 mg - drugs for constipation

European Union - English - EMA (European Medicines Agency)

immunomedics gmbh - sulesomab - osteomyelitis; radionuclide imaging - diagnostic agents - this medicinal product is for diagnostic use only.leukoscan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.leukoscan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.

European Union - English - EMA (European Medicines Agency)

lipomed gmbh - cladribine - leukemia, hairy cell - antineoplastic agents - litak is indicated for the treatment of hairy-cell leukaemia.

European Union - English - EMA (European Medicines Agency)

biopartners gmbh - ribavirin - hepatitis c, chronic - antivirals for systemic use - ribavirin biopartners is indicated for the treatment of chronic hepatitis-c-virus (hcv) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. ribavirin monotherapy must not be used. there is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).naïve patientsadult patientsribavirin biopartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid (hcv-rna) (see section 4.4)children three years of age and older and adolescentsribavirin biopartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna.when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis (see section 4.4).previous-treatment-failure patientsadult patientsribavirin biopartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis c who have previously responded (with normalisation of alt at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).